Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 4th. The trade occurred in the Representative’s “MERRILL LYNCH SIMPLE MANAGED ACCOUNT” account.
Representative Michael A. Rulli also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 11/12/2026.
- Sold $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 11/4/2026.
- Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/4/2026.
- Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 11/4/2026.
- Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 10/28/2026.
- Sold $50,001 – $100,000 in shares of Alphabet (NASDAQ:GOOG) on 10/16/2026.
- Sold $1,001 – $15,000 in shares of WesBanco (NASDAQ:WSBC) on 10/16/2026.
- Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/28/2026.
- Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 9/3/2026.
- Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 9/3/2026.
Eli Lilly and Company Price Performance
LLY opened at $1,346.40 on Friday. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,475.25. The firm has a 50-day moving average price of $1,268.06 and a 200-day moving average price of $1,119.25. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $1.27 trillion, a price-to-earnings ratio of 44.81, a PEG ratio of 1.71 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the previous year, the business earned $7.02 EPS. Equities analysts expect that Eli Lilly and Company will post 35.72 EPS for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.
Recent Eli Lilly and Company Headlines
Here are a few of the latest headlines about LLY:
- Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
- Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope
- Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares
Wall Street Analyst Weigh In
A number of brokerages recently commented on LLY. Jefferies Financial Group upped their target price on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a report on Monday, November 9th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. BMO Capital Markets reiterated an “outperform” rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,422.00.
Get Our Latest Stock Analysis on Eli Lilly and Company
Insider Activity
In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $13,522,666,000. Jupiter Topco LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $4,667,180,000. Corient Private Wealth LP bought a new position in Eli Lilly and Company during the second quarter valued at about $764,116,000. BlackRock Inc. raised its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Eli Lilly and Company by 27.4% in the third quarter. American Century Companies Inc. now owns 3,000,403 shares of the company’s stock worth $3,471,714,000 after acquiring an additional 645,566 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.
About Representative Rulli
Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio’s 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027.
Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio’s 6th Congressional District. He declared candidacy for the 2026 election.
Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli’s career experience includes working as the director of operations with Rulli Bros. Markets.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
